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Association of cyclophilin A with renal brush border mem- cytosolic extract from lymphocytes and to possess high
branes: Redistribution by cyclosporine A. affinity for CsA [1]. Following the identification of CypA,
Background. Administration of the immunosuppressive agent other members of the cyclophilins were cloned and char-cyclosporine A (CsA) is associated with nephrotoxicity. The
acterized. These cyclophilins (CypB, CypC, CypD, andmain target for CsA, cyclophilin A (CypA), was found in high
Cyp40) were found to be less abundant and located notlevels in epithelial cells of renal proximal tubules. In the present
study, CypA was immunodetected and characterized following only in cytosol, but also in membranes and subcellu-
CsA treatment in subcellular fractions of renal cortex. lar organelles because of the presence of hydrophobic
Method. The renal content and distribution of CypA was N-terminal signal as well as C-terminal extensions [5–8].evaluated in untreated rats and in rats treated with a subcutane-
More recently, Cyp40 and CypA were shown to be a partous injection of CsA (10 mg · kg21 · day21) for 10 days.
of a cytosolic heat-shock protein-immunophilin chaper-Results. In untreated rats, membrane-bound CypA repre-
sents 0.25% of total brush border membrane (BBM) proteins, one complex that also includes caveolin, heat-shock pro-
similar to the proportion found in the soluble fraction. High tein 56, and cholesterol [9]. CsA binds to this conserved
ionic strength treatment was unable to extract CypA from
family of abundant proteins [10, 11] that are expressedBBMs, whereas alkaline treatment (Na2CO2, pH 11) and deter-
in various intracellular compartments in most, if not all,gent 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propane-
sulfate (CHAPS) released it from BBMs. These results indicate organisms [1, 12–14].
that CypA is associated with renal BBMs, and that hydrophobic The cyclophilins possess a peptidyl-prolyl cis-trans iso-
interactions are involved in this association. The CypA distribu- merase activity (PPIase) and are thought to be involved
tion was strongly modified in both BBMs and the soluble frac-
in protein folding via cis-trans isomerization of prolinetion after CsA treatment, but its affinity for CsA estimated by
residues [12, 13]. This PPIase activity suggests that CypAphotoaffinity labeling was unaffected. The CypA expression
level decreased by 45% in BBMs, while it increased by 33% may act as a molecular chaperone, facilitating protein
in the soluble fraction, compared with control rats. CypA re- folding and protein trafficking [12, 15]. CsA binds tightly
mained associated with the membranes following in vitro incu- to CypA and inhibits its PPIase activity. However, the
bation of renal BBMs with CsA. However, incubation of CypA
inhibition of the PPIase activity by CsA and many of CsAwith one of its substrates released CypA from renal BBMs.
analogues does not correlate with their immunosuppres-Conclusions. These experiments suggest that renal BBMs
sion activities [3, 16]. Immunosuppression was found tocontain a significant amount of CypA and chronic exposure to
CsA, and acute exposure to one of CypA substrates may modify be dependent on inhibition of calcineurin, a Ca21-calmod-
its subcellular distribution. ulin–dependent phosphatase [17]. For its immunosup-
pressive activity, the exposed portion of CsA in the CsA-
cyclophilin complex binds to calcineurin. Formation of
Cyclophilin A (CypA) has been identified as the main this complex inhibits the serine-threonine phosphatase
target for the immunosuppressive agent cyclosporine A activity of calcineurin [10], thus blocking all subsequent
(CsA) [1–4]. This protein was shown to be abundant in steps in the immunostimulatory signal transduction path-
way of T cells [18].
Cyclophilin A is widely distributed in almost all tissuesKey words: nephrotoxicity, immunosuppression, cyclophilins, protein
folding, renal cortex. in prokaroyotes and eukaryotes. In humans, CypA was
found in all organs, and concentrations were between 1Received for publication May 13, 1999
and 3 mg/mg protein [19]. Immunostaining at the cellularand in revised form October 7, 1999
Accepted for publication November 1, 1999 level indicated not only cytoplasmic but also nuclear
localization of CypA [20]. More particularly, relativelyÓ 2000 by the International Society of Nephrology
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high levels of CypA were found in the kidney [19, 20]. Preparation of nucleus, mitochondria, microsomes,
and intracellular membranesA distinct regional distribution of CypA was observed
in this tissue, where proximal tubular epithelial cells were Renal cortex (10 mg/g) was homogenized in buffer
reported to contain distinctly more CypA than the other containing 2.4 mol/L sucrose and 3.3 mmol/L CaCl2. The
structures and glomeruli. The mRNA encoding CypC, homogenate was filtered through a cheese cloth, and the
another member of the cyclophilin family, was also shown filtrate was centrifuged at 40,000 3 g for one hour. The
pellet was resuspended in 1 mol/L sucrose and 1 mol/Lto be expressed in the kidney [21]. In a previous study,
CaCl2 and was centrifuged at 3000 3 g for five minutes.the nephrotoxicity effects of CsA were proposed to be
Then the final pellet was resuspended in 250 mmol/Lmediated through the binding to renal CypA, which caused
sucrose and 1 mmol/L CaCl2. For mitochondria and mi-the inhibition of calcineurin phosphatase activity [22].
crosome preparations, renal cortex (10 mL/g) was ho-In the present study, we report an abundant occurrence
mogenized in 250 mmol/L sucrose, 5 mmol/L Tris/HCl,of cyclophilin in both soluble fraction and brush border
pH 7.5, and 1 mmol/L ethylenediaminetetraacetic acidmembranes (BBMs) from renal cortex. We have charac-
(EDTA). The homogenate was centrifuged at 600 3 gterized the effects of various agents on the association
for 10 minutes, and the supernatant was centrifuged atof CypA with BBMs. We analyzed the photoaffinity la-
8500 3 g for 10 minutes. This pellet, washed twice, consti-beling of CypA associated with BBMs by diazirine-CsA
tuted the enriched mitochondria fraction. The superna-(SDZ 212-122) and compared it with the one obtained
tant was centrifuged at 40,000 3 g for 20 minutes. Thefor CypA in soluble fraction and human recombinant
supernatant obtained was then centrifuged at 100,000 3 g
CypA. To our knowledge, this is the first report demon-
for one hour. The final pellet corresponded to the en-
strating an association of CypA with renal BBMs that riched microsomes fractions. For the preparation of in-
could be modulated by a CypA substrate (Suc-Ala-Ala- tracellular membranes (IMs), kidney homogenate was
Pro-Phen-pNa peptide) and CsA. centrifuged at 40,000 3 g for 20 minutes to remove un-
broken cells, nuclei, and plasma membranes. The super-
natant was then centrifuged at 100,000 3 g for one hourMETHODS
at 48C to obtain the IMs. The various membrane prepara-
Materials tions were resuspended in 50 mmol/L mannitol, 5
mmol/L HEPES/Tris, pH 7.5, and were stored at 2 08C.Sprague-Dawley male rats (300 to 350 g) were pur-
chased from Charles River (St.-Constant, Quebec, Can-
Cyclosporine A treatmentada). The Mini-Protean II apparatus and electrophoresis
Male Sprague-Dawley rats were treated with subcuta-reagents were from Bio-Rad (Mississauga, Ontario, Can-
neous injections of CsA. For all treatments, each groupada). Polyvinylidene difluoride (PVDF) membranes and
of animals comprised three rats. CsA was used in physio-Milliblot-Graphite electroblotter I were from Millipore
logical buffer containing 147 mmol/L NaCl, 4 mmol/L(Mississauga, Ontario, Canada). Antirabbit, antimouse
KCl, 3 mmol/L CaCl2, 1.2 mmol/L MgCl2, 5 mmol/LIgG horseradish peroxidase-linked whole antibody and en-
glucose, and 15 mmol/L HEPES/Tris, pH 7.4, with 15%hanced chemiluminescence (ECL) reagents were bought
(wt/vol) Cremophor EL (CrEL) and 3% (wt/vol) etha-from Amersham (Oakville, Ontario, Canada). The poly-
nol. The control group received the CsA vehicle (physio-clonal antibody (pAb) directed against CypA was pur-
logical buffer, CrEL, and ethanol), and the treated groupchase from BioMol (Plymouth Meeting, PA, USA). The
was injected daily with CsA (10 mg · kg21 · day21) forCsA analogue (SDZ 212-122), the parent drug CsA, and
10 days. Rats were sacrificed 24 hours after the last injec-the monoclonal antibody (mAb) against CsA were
tion. Kidneys from individual animals were pooled, and
kindly provided by Dr. R.M. Wenger (Novartis, Basle,
renal BBMs and soluble fraction were prepared as men-
Switzerland).
tioned previously.
Preparation of brush border membranes and Detection of cyclophilin A by Western blot analysis
soluble fractions
Brush border membranes or soluble fraction proteins
Renal BBMs were prepared by a MgCl2 precipitation were resolved by sodium dodecyl sulfate-polyacrylamide
method as described previously [23]. The final pellet con- gel electrophoresis (SDS-PAGE) on 12.5% acrylamide
taining purified BBMs was resuspended in 300 mmol/L gels according to the method of Laemmli, with a Mini-
mannitol, 20 mmol/L HEPES/Tris, pH 7.5, and was Protean II apparatus [24]. The proteins were transferred
stored at 2808C. The supernatants obtained at the time electrophoretically onto a 0.45 mm pore size PVDF mem-
of BBM precipitation were centrifuged at 100,000 3 g brane with a semidry electroblotter apparatus. The trans-
fer was carried out at 1 mA/cm2 for 90 minutes with 96for 60 minutes to prepare the soluble fractions.
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mmol/L glycine, 10 mmol/L Tris, and 10% methanol. of protein) was detected by Western blot analysis using
a pAb directed against CypA (Fig. 1A). The content ofPVDF membranes were incubated for 120 minutes at
258C in Tris-buffered saline (50 mmol/L Tris and 150 this 18 kD protein was higher in the homogenate, fol-
lowed by BBM, soluble fraction, nucleus, mitochondria,mmol/L NaCl, pH 7.0) containing 0.1% Tween-20 (TBS-T)
and the anti-CypA pAb (2.5 mg/mL). The membranes and microsomes. CypA was neither enriched in soluble
fraction or BBM, while the enrichment of alkaline phos-were washed three times for 15 minutes in TBS-T and
were incubated for 60 minutes with horseradish peroxi- phatase in these membranes was around 10- to 12-fold
over the homogenate. This may be explained by the factdase-conjugated antirabbit IgG diluted 1/1000 in TBS-T
containing 5% powdered milk. The membranes were that CypA was not restricted to one of these two cellular
compartments. The CypA in soluble fraction and BBMfinally washed three times in TBS-T for 15 minutes, and
the immune complex was revealed with ECL reagents. was immunodetected and compared with a standard
curve established with different amounts of human recom-Protein concentrations were estimated with the Bradford
assay [25]. binant CypA. According to this calibration curve, the
estimated CypA concentration was around 2.5 mg/mg in
Photolabeling of cyclophilin A with diazirine- homogenate and BBM, 2 mg/mg in soluble fraction, and
cyclosporine A analogue 0.5 mg/mg in nucleus, mitochondria, and microsomes.
In addition, the detection of prenylated protein meth-Brush border membranes or soluble fraction proteins
(40 mg) were incubated with diazirine-CsA in 10 mmol/L yltransferase (PPMT), a 33 kD protein specifically local-
ized in the endoplasmic reticulum [26], was also per-Tris/HCl, pH 7.0, and protease inhibitors (2 mg/mL apro-
tinin, 10 mg/mL pepstatin A, and 100 mg/mL bacitracin) formed using 40 mg of protein from untreated soluble
fraction, IMs, and renal BBMs (Fig. 1B). PPMT wasfor 60 minutes at 258C, and then were irradiated under a
Spectroline ultraviolet lamp (Fisher Scientific, Montreal, detected only in IMs, suggesting that the presence of
CypA in BBM is not due to contamination by other IMs.Quebec, Canada) at 254 nm on ice. Sample buffer was
added to the suspensions, and proteins were resolved by This is in agreement with a previous study in which
we showed that BBMs are not enriched in various IMSDS-PAGE on 12.5% acrylamide gels according to the
method of Laemmli [24] with a Mini-Protean II appara- markers [27].
Cyclophilin A was also immunodetected after poly-tus. The proteins were transferred electrophoretically
onto a 0.45 mm pore size PVDF membrane with a semi- acrylamide gel electrophoresis performed under reducing
and nonreducing conditions with heated and nonheateddry electroblotter apparatus. The transfer was carried
out at 1 mA/cm2 for 90 minutes with 96 mmol/L glycine, samples (Fig. 1C). These procedures are usually used
to reduce disulfide bonds and to minimize proteolytic10 mmol/L Tris, and 10% methanol. PVDF membranes
were incubated for 120 minutes at 258C in Tris-buffered cleavage by endogenous proteases. The reducing agent,
b-mercaptoethanol, in the presence of SDS permits thesaline (50 mmol/L Tris and 150 mmol/L NaCl, pH 7.0)
containing 0.2% Tween-20 (TBS-T) and the anti-CsA dissociation of proteins with disulfide cross-link into their
subunits. When this reducing agent was added to bothmAb (2.5 mg/mL). The membranes were washed three
times for 15 minutes in TBS-T and incubated for 60 renal BBMs and the soluble fraction samples, CypA was
detected as a 18 kD protein. In the soluble fraction, otherminutes with horseradish peroxidase-conjugated anti-
mouse IgG diluted 1/1000 in TBS-T containing 5% pow- bands at 60, 40, 38, and 30 kD were also revealed by the
pAb directed against CypA. Boiling the samples had nodered milk. The membranes were finally washed three
times in TBS-T for 15 minutes, and the immune complex effect on CypA detection in both fractions. However,
under nonreducing conditions (in absence of b-mercapto-was revealed with ECL reagents.
ethanol), the immunodetection profile of CypA was
Densitometric analysis strongly affected. In these conditions, no immunoreac-
tive band was revealed at 18 kD, and only one strongThe intensity of the bands obtained from Western blot
analysis and from the photolabeling experiments was band with a high molecular weight (.200 kD) was ob-
served in the soluble fraction. These results indicate thatestimated with a Personal densitometer SI (Molecular
Dynamics, Sunnyvale, CA, USA). electrophoresis under reducing conditions is essential for
CypA detection by Western blot.
RESULTS Effect of cyclosporine A treatment on renal
cyclophilin A content, and cyclophilin A’s affinityImmunodetection of cyclophilin A in subcellular
extracts from renal cortex for cyclosporine A
Because CypA is a target for the immunosuppressiveSubcellular extracts (soluble fraction, BBM, nucleus,
mitochondria, microsomes) were isolated from rat renal agent CsA, rats were treated with this drug to determine
whether it may induce a release of CypA associated withcortex. The CypA in these subcellular extracts (10 mg
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Fig. 1. Immunodetection of cyclophilin A (CypA). (A) Subcellular fractions of renal cortex were isolated as described in the Methods section.
Equal amounts of proteins (10 mg) from renal cortex homogenate (H), brush border membranes (BBMs), soluble fraction (SF), nucleus (Nu),
mitochondria (Mt), and microsomes (Mc) were loaded onto 15 wells of a 12.5% acrylamide gel and separated by SDS-PAGE. CypA was detected
by Western blot analysis using a polyclonal antibody (pAb) directed against CypA and enhanced chemiluminescence (ECL) reagents. A standard
curve using recombinant CypA (0 to 0.05 mg) was also performed, and the densities corresponding to the levels of CypA in the various subcellular
fractions are indicated by arrows. (B) As a control, phenylated protein methyltransferase (PPMT) was immunodetected in 40 mg of protein from
renal SF, BBM, and intracellular membranes (IMs) using a pAb developed in our laboratory that is directed against the amino acid residues 207 to
218 of PPMT from Xenopus laevis. (C) CypA was immunodetected in 20 mg of protein from renal BBM and SF following eletrophoresis under reducing
and nonreducing conditions using a 10-well polyacrylamide gel. Leammli sample buffer with or without b-mercaptoethanol (b-EtOH) was used,
and samples were boiled (1 heat) or not boiled (2 heat) for five minutes prior to SDS-PAGE. One representative experiment is shown (N 5 3).
BBM. Rats received subcutaneous injections of CsA (10 unchanged after CsA treatment in renal BBM or soluble
fraction (data not shown). These results indicate that anmg · kg21 · day21) for 10 days. Soluble fraction and BBMs
were purified from the kidney cortex of the different rat equal amount of proteins was applied to the Western
blots, and the results suggest that the changes in thegroups 24 hours after the last injection. The enrichment
values of g-glutamyltranspeptidase activity for all BBM CypA content in BBM and soluble fraction are not
caused by a physical entrapment of soluble CypA inpreparations were similar for the control (8.3 6 0.7) and
treated (8.7 6 0.6) groups. In the present study, the renal BBM. The levels of CypA, b-actin, and RhoGDI
were also evaluated in samples isolated from rats forCypA content and affinity for CsA were evaluated after
this CsA treatment. The CypA content after CsA treat- four days after a single administration of the nephrotoxic
agent cisplatin at 5 mg/kg. This dose of cisplatin corre-ment was evaluated in renal homogenate and both solu-
ble fraction and renal BBM (Fig. 2A). As controls, sponds to chemotherapeutic levels known to induce mild
renal failure in rats [28–30]. We chose day 4 for collectingRhoGDI, a cytosolic regulatory protein of Rho, and
b-actin were also detected in the same samples by West- renal samples because it has been reported that renal
insufficiency and functional alterations caused by cis-ern blot. RhoGDI was present in renal homogenate and
soluble fraction, which is in agreement with its cytosolic platin are maximal on days 3 to 5 after treatment with
this agent. The levels of CypA were unaffected in bothlocalization, whereas b-actin was mainly detected in re-
nal BBM. The content of both RhoGDI and b-actin, soluble fraction and renal BBM by cisplatin, suggesting
that the redistribution of CypA is specific to CsA andas well as other membrane-bound proteins of the small
G-protein family such as Ras, Rho A and Rho B, was that the molecular events that lead to the nephrotoxicity
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Fig. 2. CypA content in renal BBM and soluble fraction after CsA treatment. (A) For cyclophilin A (CypA), equal amounts of proteins (20 mg)
from renal homogenate (Homo), soluble fraction (SF), and brush border membrane (BBM) isolated from control (C) and treated (T) rats were
resolved by SDS gel electrophoresis with a 12.5% polyacrylamide gel. Immunoblots were performed with a pAb against CypA, as described in
the Methods section. As a control, RhoGDI and b-actin were immunodetected in the same samples using a pAb as previously described [34]. The
levels of CypA, b-actin, and RhoGDI were evaluated also in samples (20 mg of proteins) isolated from control rats and rats treated with a single
subcutaneous injection of cisplatin (5 mg/kg) as previously performed [30]. (B) The band corresponding to CypA was scanned by laser densitometry,
and the content of CypA in renal fractions from CsA-treated rats was expressed as a percentage of CypA present in corresponding fractions from
control rats. One representative experiment is shown (N 5 3 different CsA treatments or cisplatin treatments).
of both drugs are different. Data obtained from three (data not shown). In the absence of CsA, densitometric
analysis from three different CsA treatments indicateddifferent CsA-treatments indicated that CypA levels in-
creased by 33 6 9% in the soluble fraction, whereas the that CypA photolabeling in the BBM isolated from rats
treated with CsA was reduced by 49 6 10% (Fig. 3A).content of CypA in renal BBM decreased by 45 6 10%,
suggesting a release of CypA from BBM (Fig. 2B). This reduction in the photoaffinity labeling of CypA
by diazirine-CsA was similar to the decrease in CypAPhotolabeling of CypA with diazirine-CsA (SDZ 212-
122) in both BBM and soluble fractions from renal cortex content associated with these BBMs (45%). In contrast,
the photolabeling of CypA in the soluble fraction iso-of control and treated rats was performed to determine
whether CypA from treated rats retained its ability to lated from treated rats evaluated in absence of CsA was
reduced by 37 6 10%, while the CypA content increasedinteract with CsA (Fig. 3). Photolabeling of CypA was
performed by incubating soluble fraction and renal BBM by 33 6 9% (Fig. 3C).
In BBM samples, the photolabeling of the CsA/CypAproteins with diazirine-CsA (1 mmol/L) and increasing
concentrations of CsA followed by irradiation. CsA bound complex decreased in the presence of increasing concen-
trations of CsA (Fig. 3B). The concentrations of CsAto CypA was detected by Western blot analysis using
a mAb directed against CsA. The CsA/CypA complex that reduced the photolabeling of CypA by 50% were
identical (0.24 6 0.02 and 0.23 6 0.01 mmol/L) for BBMmigrated as a 19 kD protein. This complex was also
immunodetected using a pAb directed against CypA isolated from control or treated rats. The photolabeling
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Fig. 3. Photolabeling of CypA in the presence of increasing concentrations of CsA. Photolabeling of CypA in renal BBM (A) and soluble fraction
(C) from both control and treated rats was performed. Equal amounts of proteins (40 mg) were incubated with diazirine-CsA (1 mmol/L) and
increasing concentrations of CsA (0 to 2.5 mmol/L) for 60 minutes at 258C. After irradiation, CsA bound to CypA was detected by Western blot
analysis using a mAb directed against CsA, as described in the Methods section. The density of the photolabeled CypA complex in renal BBM
(B) from control (d) and treated (s) rats was expressed as a function of the CsA concentration. (D) The density of the photolabeled CypA
complex in soluble from control (d) and treated (s) rats was also expressed as a function of the CsA concentration. When the remaining
concentration of CsA was taken into consideration, we obtained a new corrected curve (h). Values represent means 6 SEM obtained following
two different CsA treatments.
of CypA by diazirine-CsA was different in the soluble CypA photolabeling by diazirine-CsA in soluble frac-
tions from control and treated rats was similar at 0.15 6fraction from CsA-treated rats compared with that from
0.04 vs. 0.19 6 0.03 mmol/L, respectively. The endoge-control animals (Fig. 3D). The CsA concentration needed
nous CsA remaining in the soluble fraction after CsAto reduce by 50% the photolabeling of CypA in soluble
administration thus explained the decrease of CypA pho-fractions isolated from treated rats was 0.34 6 0.04
tolabeling observed for this fraction in absence of exoge-mmol/L compared with 0.15 6 0.03 mmol/L for soluble
nous CsA (0 mmol/L) in Fig. 3C.fractions from control rats. To verify whether the differ-
ence observed between these two values could be related Extraction of cyclophilin A from renal brush
to the presence of CsA that remains in the soluble frac- border membranes
tion of treated rats, the concentration of CsA was esti-
Different agents and conditions were tested to charac-mated by high-performance liquid chromatography. The
terize the association of CypA with BBMs (Fig. 4). BBMCsA concentration determined by high-performance liq-
was incubated in homogenate buffer (low osmotic me-uid chromatography (HPLC) in the soluble fraction after
dium) and in 1 mol/L NaCl, 0.5% 3-[(3-cholamidopro-a 10-day treatment was around 1280 ng/L (approximately
pyl)-dimethyl-ammonio]-1-propane-sulfate (CHAPS),
1 mmol/L). This concentration of CsA in the soluble or 0.2 mol/L Na2CO3, pH 11 (Fig. 4A). The suspensionsfraction from treated rats corresponds to a final concen- were then centrifuged, and the CypA content was evalu-
tration of 0.15 to 0.2 mmol/L in the photolabeling assay. ated by Western blots of pellets and supernatants. After
This concentration of CsA reduced by 50% the photola- the incubation in low osmotic conditions or in high ionic
beling of CypA in the soluble fraction from the control strength, the major portion of CypA was detected in the
group. Thus, the density obtained for the CsA-treated pellet, suggesting that CypA remained associated with
soluble fraction measured in absence of exogenous CsA renal BBM. In contrast, the CypA after the incubations
(0 mmol/L) was corrected by a factor of 2, and each CsA with CHAPS or Na2CO3, pH 11, was mainly found in
concentration was also corrected for remaining CsA. These the supernatant. These results also suggest that there are
corrected density values (%) and CsA concentrations at least two populations of CypA in BBM, one that is
were plotted (Fig. 3D). From this corrected curve, the strongly associated with the membranes and another that
could be more easily extracted from the membranes.estimated CsA concentration that displaced by 50% the
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respectively. These results suggest that under normal con-
ditions, CypA may be released from the membrane by
its substrates. In addition, various amounts of CypA were
released from BBMs in controls that we performed in
Figure 4. This may be explained by the fact that controls
in Figure 4 B and C were performed using homogenate
buffer containing either 2% ethanol and 1% trifluoro-
ethanol. Thus, the presence of both solvents may inter-
fere with membrane lipids and modify the release of
CypA from BBM. This may also indicate the presence
of two CypA populations in renal BBM, one that is
strongly associated to the membrane, whereas the second
population is more affected by both solvents. Further
studies are now being carried out to determine and char-
acterize what type of interactions may be involved in
the association of CypA with renal BBM.
DISCUSSION
In this study, the subcellular localization of CypA was
performed by Western blotting analysis using a pAb
directed against CypA. This protein was detected under
reducing conditions in all examined subcellular compart-
Fig. 4. Extraction of CypA from renal BBMs. (A) BBM proteins (45 ments of rat kidney cortex, including the soluble fraction,
mg) were incubated in the homogenate buffer (HB) containing 50 mmol/L BBM, mitochondria, microsomes, and the nucleus. Previ-
mannitol and 5 mmol/L HEPES/Tris, pH 7.5, 1 mol/L NaCl, 0.5%
ous studies have shown that CypA was mainly presentCHAPS, or 0.2 mol/L Na2CO3, pH 11. (B) BBM proteins (45 mg) were
incubated in the presence of 2% ethanol as the control (EtOH), 10 in the cytosol [19, 20, 31]. However, CypA was also de-
mmol/L CsA or CsH. (C) Equal amounts of BBM proteins (45 mg) were tected in many other subcellular compartments such asalso incubated in homogenate buffer containing 1% trifluoroethanol, 5
the nucleus, mitochondria, microsomes, and Golgi appa-mmol/L LiCl, and 0, 50, or 100 mmol/L of Suc-Ala-Ala-Pro-Phen-pNA
peptide. After one hour of incubation at 378C, the samples were centri- ratus of various tissues such as the kidney, the liver, and
fuged. Proteins from the pellet (P) and the supernatant (S) of each the intestines [29, 30]. Our results show that the CypAsample were separated by SDS-PAGE, and their CypA content was
concentration is high in renal BBM compared with otherevaluated by Western blot. One representative experiment of three
different experiments performed in duplicate is shown. IMs and compartments. The absence of enrichment of
CypA in soluble fraction or renal BBM is explained by
the presence of CypA in various cellular compartments.
In normal mammalian tissues, the CypA concentrationTo determine whether the redistribution of CypA be-
may account for as much as 0.1 to 0.4% of total proteintween BBM and soluble fraction from renal cortex was
in the cell [19, 20, 32]. We evaluated the concentrationcaused by a direct interaction of the drug with CypA,
of CypA by immunodetection to be between 2 and 2.5renal BBMs were incubated in vitro with CsA (Fig. 4B).
mg/mg in soluble fraction and in BBM of renal cortex.As a control, BBMs were also exposed to cyclosporine
The presence of CypA in the BBM is not related to anH (CsH), a natural cyclosporine that does not interact
entrapment of CypA during their isolation since RhoGDI,with CypA. Following the incubations with 10 mmol/L
a cytosolic regulatory protein for Rho found in the kid-CsA or CsH, BBMs were centrifuged, and the CypA
ney [33] and of similar size to that of CypA, was detectedcontent was evaluated in the pellet or supernatant. Nei-
in soluble fraction, as expected, but not in renal BBMs.ther CsA or CsH affected the release of CypA from
Our results indicate that CypA in both renal fractionsBBM because the CypA content in supernatant and pel-
was detected as a 18 kD protein when electrophoresislet remained similar to the control. These results suggest
was performed in the presence of the reducing agentthat chronic CsA administration is required to change
b-mercaptoethanol. In the renal soluble fraction, otherthe CypA content in BBM.
bands of higher molecular sizes were also revealed byThe Suc-Ala-Ala-Pro-Phen-pNa peptide, a PPIase
Western blot. These bands were completely absent insubstrate, was used in an attempt to displace the CypA
renal BBM. These bands could represent other CypAassociated with BBM (Fig. 4C). In contrast with the
isoforms or CypA oligomeric forms that are resistant toprevious results obtained with CsA, incubation of BBM
the denaturating conditions used for the gel electropho-for one hour with 50 or 100 mmol/L of this CypA sub-
strate increased the release of CypA by 25 and 85%, resis. When b-mercaptoethanol was omitted during gel
Demeule et al: Characterization of CypA in renal BBMs 1597
electrophoresis, a strong band that may be related to gesting that the affinity of CypA for CsA had changed,
CypA was revealed only in renal soluble fraction as a although it remained similar in the BBM. However,
.200 kD protein. These results suggest that electropho- when the data were corrected for CsA remaining in the
resis should be carried out in the presence of a reducing soluble fraction following CsA treatment to the animals,
agent for the detection of CypA at the right molecular the affinity for CsA was very similar in both populations.
size by Western blot. In addition, these results indicate On the other hand, the affinity of CypA for CsA mea-
that the antigen of CypA in renal BBM is masked in sured in BBM from control and CsA-treated rats was
absence of b-mercaptoethanol and that studies that are similar, indicating that the remaining CsA concentration
performed in the absence of reducing agent may not in membranes was negligible, probably because of the
detect CypA in these membranes. washing steps performed during the preparation of BBM.
The presence of CypA associated with membranes In addition to its high affinity for CsA, the cyclophilins
was previously reported in rat tissues, where it was ex- possess a PPIase activity [12]. The substrate used in vitro
tractable with urea or CHAPS and represented 5 to 12% to measure this PPIase activity is the Suc-Ala-Ala-cis-
of the soluble CypA [34]. In addition, the recruitment Pro-Phen-pNa peptide. In this article, the effect of this
of CypA from the mitochondrial matrix into the internal substrate and CsA on the release of CypA from BBMs
mitochondrial membrane under oxidative stress was also was evaluated. Only the Suc-Ala-Ala-Pro-Phen-pNA
reported [35]. Our results suggest that a portion of CypA peptide increased the release of CypA from renal BBMs.
in renal cortex is associated with BBMs. To characterize The exact molecular mechanism involved in the release
the association and the nature of the attachment of CypA of CypA from BBMs by this peptide remains to be estab-
with BBMs, the extraction of CypA from BBMs was lished. However, this result suggests that the binding of
performed with various agents. The addition of high ionic this CypA substrate may induce a conformational change
strength to the incubation medium did not increase the in CypA, which reduces its membrane attachment. The
release of CypA from BBMs, but treatment of BBMs molecular mechanism by which CsA treatment alters
with Na2CO3, pH 11, caused a 92% release of CypA CypA content remained unclear. However, because the
associated with these membranes, suggesting that CypA Suc-Ala-Ala-Pro-Phen-pNa peptide substrate caused
in BBMs is a peripheral membrane protein, since this also a release of CypA from the renal BBM, one possibil-
alkaline treatment does not cause the release of integral ity that may explain the redistribution of CypA during
membrane proteins. Finally, the detergent CHAPS CsA treatment could be an accumulation of cis-proline
caused a complete release of CypA associated with residues in the soluble fraction caused by the inhibition
BBM, indicating that the attachment of CypA with BBM of CypA by CsA. This redistribution of CypA could also
may involve hydrophobic interactions with either mem-
be related to secondary effects associated with the ad-
brane lipids or proteins.
ministration of CsA such as changes in renal tubules.Cyclophilin A has been reported to be highly ex-
However, the levels of Ras and b-actin as well as thepressed in the kidney, and it was suggested that CypA
activity of aminopeptidase and various sodium-depen-may be the main receptor for CsA in renal tissue extracts
dent transporters measured in a previous study using iden-[22]. Our results indicate that CsA changes the CypA
tical CsA treatment [38] were unaffected, suggesting thatcontents of BBM and soluble fraction from renal cortex.
the effect observed for CypA is not caused by a generalThese changes are rather specific, as other protein levels
degradation of renal BBMs.such as RhoGDI, Ras, and RhoB in both BBM and
In conclusion, our results show that under normalsoluble fraction remained similar after CsA treatment.
physiological conditions, CypA is also associated withThis increase in the cytosolic content of CypA is in agree-
renal BBM. Changes in CypA levels in BBM after CsAment with a previous report that CsA treatment modifies
administration or after an incubation with one of its sub-the cytosolic CypA level, as measured by confocal mi-
strates indicate also that CypA is in equilibrium betweencroscopy and quantitative immunofluorescence [36].
these two subcellular compartments. The role of theHowever, in the present study, total CypA content in
CypA associated with the BBM remains to be estab-kidney homogenate from CsA-treated rats remained un-
lished. However, it has been shown that CypB may actchanged compared with control rats, suggesting a redis-
as a chaperone molecule for membrane proteins [6, 39].tribution of CypA during CsA administration rather than
From these latter studies and the common biochemicalan increase in total CypA.
properties of CypA and B, we could speculate that theIn the present study, the photolabeling of CypA with
CypA associated with BBM may have a similar functiondiazirine-CsA was also performed as we previously de-
for the plasma membrane proteins of the renal proximalscribed for P-glycoprotein [37]. After the administration
tubules. Future studies are needed to identify and estab-of CsA to rats, the concentration needed to displace
lish the molecular mechanism involved in the associationCypA photolabeling by diazirine-CsA was increased in
soluble fractions isolated from treated animals, sug- of CypA with renal BBMs.
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